Home » Stocks » AUTL

Autolus Therapeutics PLC (AUTL)

Stock Price: $5.52 USD -0.41 (-6.91%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 390.33M
Revenue (ttm) 1.65M
Net Income (ttm) -145.49M
Shares Out 70.58M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $5.52
Previous Close $5.93
Change ($) -0.41
Change (%) -6.91%
Day's Open 5.92
Day's Range 5.47 - 6.01
Day's Volume 2,316,881
52-Week Range 4.60 - 16.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the ...

1 week ago - GlobeNewsWire

LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

2 weeks ago - GlobeNewsWire

LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

1 month ago - GlobeNewsWire

Monday's futures were relatively flat, with the Nasdaq looking the best out of the group with about a 0.2% gain.

Other stocks mentioned: CMG, KMI, WEN, CLB, CQP, CRSP, DHX ...
1 month ago - 24/7 Wall Street

Autolus Therapeutics plc (NASDAQ: AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and r/r Adult Acute Lymphobla...

1 month ago - Benzinga

Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence

1 month ago - GlobeNewsWire

- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells - - Data suggest that long term durab...

1 month ago - GlobeNewsWire

Attendance in person is not permitted

2 months ago - GlobeNewsWire

Autolus Therapeutics PLC Sponsored ADR (AUTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into...

2 months ago - Zacks Investment Research

The company announced encouraging clinical trial data for its experimental cell therapy, AUTO1.

2 months ago - The Motley Fool

AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients

2 months ago - GlobeNewsWire

- Conference call to be held on May 6, 2021 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 6, 2021 at 8:30 am ET/1:30 pm BST -

2 months ago - GlobeNewsWire

LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...

3 months ago - GlobeNewsWire

LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...

3 months ago - GlobeNewsWire

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...

3 months ago - GlobeNewsWire

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...

3 months ago - GlobeNewsWire

Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

4 months ago - Zacks Investment Research

LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the ...

5 months ago - GlobeNewsWire

Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for t...

5 months ago - Benzinga

LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the ...

5 months ago - GlobeNewsWire

LONDON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

5 months ago - GlobeNewsWire

LONDON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

5 months ago - GlobeNewsWire

Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the nea...

5 months ago - Zacks Investment Research

• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022 •  Company intends to partner...

6 months ago - GlobeNewsWire

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

6 months ago - GlobeNewsWire

AUTO3 continues to show a differentiated product profile supporting outpatient administration

7 months ago - GlobeNewsWire

Updated data from the ALLCAR study suggests AUTO1's potential for transformational activity in adult patients with r/r ALL

7 months ago - GlobeNewsWire

Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Autolus - a developer of next-generation programmed T cell therapies - has shown continued progress in advancing its anti-cancer pipeline. AUTO1 has entered a pivotal trial for ALL and may achieve regul...

8 months ago - Seeking Alpha

LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

8 months ago - GlobeNewsWire

Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

8 months ago - GlobeNewsWire

-  AUTO3 shows promise of a highly differentiated product profile

10 months ago - GlobeNewsWire

LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

10 months ago - GlobeNewsWire

Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

- Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST - - Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST -

11 months ago - GlobeNewsWire

Dr. Jay T. Backstrom appointed to board of directors Dr. Jay T. Backstrom appointed to board of directors

11 months ago - GlobeNewsWire

Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

- AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate

1 year ago - GlobeNewsWire

Is (AUTL) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Pivotal AUTO1 study in adult ALL patients enrolling

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.

1 year ago - Zacks Investment Research

Autolus Therapeutics (AUTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in ...

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Autolus Therapeutics

1 year ago - Zacks Investment Research

Autolus Therapeutics Plc (AUTL) CEO Christian Itin on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of Autolus Therapeutics (NASDAQ:AUTL) were unchanged at $10.28 after the company reported Q1 results.

1 year ago - Benzinga

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment ...

1 year ago - GlobeNewsWire

Autolus Therapeutics (AUTL) CEO Christian Itin on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

- Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab

1 year ago - GlobeNewsWire

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therape... [Read more...]

Industry
Biotechnology
IPO Date
Jun 22, 2018
Stock Exchange
NASDAQ
Ticker Symbol
AUTL
Full Company Profile

Financial Performance

In 2020, AUTL's revenue was $1.72 million, a decrease of -41.02% compared to the previous year's $2.91 million. Losses were -$142.09 million, 14.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is 15.94, which is an increase of 188.77% from the latest price.

Price Target
$15.94
(188.77% upside)
Analyst Consensus: Buy